These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 14711339

  • 21. Global and local variations in antimicrobial susceptibilities and resistance development in the major respiratory pathogens.
    Alpuche C, Garau J, Lim V.
    Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S135-8. PubMed ID: 17945468
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Reduction of nasal colonization of nontypeable Haemophilus influenzae following intranasal immunization with rLP4/rLP6/UspA2 proteins combined with aqueous formulation of RC529.
    Mason KW, Zhu D, Scheuer CA, McMichael JC, Zlotnick GW, Green BA.
    Vaccine; 2004 Sep 03; 22(25-26):3449-56. PubMed ID: 15308371
    [Abstract] [Full Text] [Related]

  • 24. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B.
    J Antimicrob Chemother; 2004 Jan 03; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [Abstract] [Full Text] [Related]

  • 25. Microbiological aspects of bacterial lower respiratory tract illness in children: typical pathogens.
    Wolf J, Daley AJ.
    Paediatr Respir Rev; 2007 Sep 03; 8(3):204-10, quiz 210-1. PubMed ID: 17868918
    [Abstract] [Full Text] [Related]

  • 26. [What to expect from vaccine prevention in acute respiratory tract infection in children?].
    Gaudelus J.
    Rev Prat; 2007 Nov 15; 57(17):1912-8. PubMed ID: 18095628
    [Abstract] [Full Text] [Related]

  • 27. Recent advances in the development of live, attenuated bacterial vectors.
    Roland KL, Tinge SA, Killeen KP, Kochi SK.
    Curr Opin Mol Ther; 2005 Feb 15; 7(1):62-72. PubMed ID: 15732531
    [Abstract] [Full Text] [Related]

  • 28. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
    Cantón R, Lode H, Graninger W, Milkovich G.
    Int J Antimicrob Agents; 2006 Sep 15; 28 Suppl 2():S115-27. PubMed ID: 16904873
    [Abstract] [Full Text] [Related]

  • 29. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA, Jones RN, Leeds JA, Denys G, Sader HS, Fritsche TR.
    J Antimicrob Chemother; 2006 May 15; 57(5):914-23. PubMed ID: 16549511
    [Abstract] [Full Text] [Related]

  • 30. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Jul 15; 52(3):187-93. PubMed ID: 16105563
    [Abstract] [Full Text] [Related]

  • 31. Toll-like receptors: their roles in bacterial recognition and respiratory infections.
    Randhawa AK, Hawn TR.
    Expert Rev Anti Infect Ther; 2008 Aug 15; 6(4):479-95. PubMed ID: 18662115
    [Abstract] [Full Text] [Related]

  • 32. Induction of a mucosal immune response by oral immunization. An overview.
    van Daal GJ, Lachmann B.
    Z Erkr Atmungsorgane; 1991 Aug 15; 177(1-2):20-34. PubMed ID: 1808849
    [Abstract] [Full Text] [Related]

  • 33. Respiratory tract immune response to microbial pathogens.
    Wilkie BN.
    J Am Vet Med Assoc; 1982 Nov 15; 181(10):1074-9. PubMed ID: 6294027
    [Abstract] [Full Text] [Related]

  • 34. Prevalence of Moraxella catarrhalis infections of the lower respiratory tract in elderly patients.
    Tamang MD, Dey S, Makaju RK, Jha BK, Shivananda PG, Bhramadatan KN.
    Kathmandu Univ Med J (KUMJ); 2005 Nov 15; 3(1):39-44. PubMed ID: 16401943
    [Abstract] [Full Text] [Related]

  • 35. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M, Shirakawa T.
    Kekkaku; 2005 Sep 15; 80(9):613-29. PubMed ID: 16245793
    [Abstract] [Full Text] [Related]

  • 36. Existing antibacterial vaccines.
    Mendoza N, Ravanfar P, Satyaprakash A, Pillai S, Creed R.
    Dermatol Ther; 2009 Sep 15; 22(2):129-42. PubMed ID: 19335724
    [Abstract] [Full Text] [Related]

  • 37. Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries.
    Walker RI.
    Vaccine; 2005 May 16; 23(26):3369-85. PubMed ID: 15837361
    [Abstract] [Full Text] [Related]

  • 38. [Immunity and pathophysiology of respiratory tract infections].
    Alonso JM.
    Med Mal Infect; 2008 Aug 16; 38(8):433-7. PubMed ID: 18692336
    [Abstract] [Full Text] [Related]

  • 39. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
    Jacobs E, Dalhoff A, Korfmann G.
    Int J Antimicrob Agents; 2009 Jan 16; 33(1):52-7. PubMed ID: 18835763
    [Abstract] [Full Text] [Related]

  • 40. Vaccination by aerosols: modulation of clearance mechanisms in the lung.
    Hensel A, Lubitz W.
    Behring Inst Mitt; 1997 Feb 16; (98):212-9. PubMed ID: 9382742
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.